The rest-activity circadian rhythm (CircAct) reflects the function of the circadian timing system. In a prior singleinstitution study, the extent of CircAct perturbation independently predicted for survival and tumor response in 192 patients receiving chemotherapy for metastatic colorectal cancer. Moreover, the main CircAct parameters correlated with several health-related quality of life (HRQoL) scales. In this prospective study, we attempted to extend these results to an independent cohort of chemotherapy-naive metastatic colorectal cancer patients participating in an international randomized phase III trial (European Organisation for Research and Treatment of Cancer 05963). Patients were randomized to receive chronomodulated or conventional infusion of 5-fluorouracil, leucovorin, and oxaliplatin as first-line treatment for metastatic colorectal cancer. Patients from nine institutions completed the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 and wore a wrist accelerometer (actigraph) for 3 days before chemotherapy delivery. Two validated parameters (I |0.25|; P < 0.01). I

Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer

TAMPELLINI, MARCO;
2009-01-01

Abstract

The rest-activity circadian rhythm (CircAct) reflects the function of the circadian timing system. In a prior singleinstitution study, the extent of CircAct perturbation independently predicted for survival and tumor response in 192 patients receiving chemotherapy for metastatic colorectal cancer. Moreover, the main CircAct parameters correlated with several health-related quality of life (HRQoL) scales. In this prospective study, we attempted to extend these results to an independent cohort of chemotherapy-naive metastatic colorectal cancer patients participating in an international randomized phase III trial (European Organisation for Research and Treatment of Cancer 05963). Patients were randomized to receive chronomodulated or conventional infusion of 5-fluorouracil, leucovorin, and oxaliplatin as first-line treatment for metastatic colorectal cancer. Patients from nine institutions completed the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 and wore a wrist accelerometer (actigraph) for 3 days before chemotherapy delivery. Two validated parameters (I |0.25|; P < 0.01). I
2009
69
11
4700
4707
Innominato PF; Focan C; Gorlia T; Moreau T; Garufi C; Waterhouse J; Giacchetti S; Coudert B; Iacobelli S; Genet D; Tampellini M; Chollet P; Lentz MA; Mormont MC; Lévi F; Bjarnason GA
File in questo prodotto:
File Dimensione Formato  
Cancer Res Innominato 2009.pdf

Accesso riservato

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 209.16 kB
Formato Adobe PDF
209.16 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Cancer Res Innominato 2009 postprint.pdf

Accesso aperto

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 532.28 kB
Formato Adobe PDF
532.28 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/75953
Citazioni
  • ???jsp.display-item.citation.pmc??? 62
  • Scopus 184
  • ???jsp.display-item.citation.isi??? 167
social impact